QUEENSLAND BAUXITE Forum: Community User: EisbärOL

Plus 100%

Wieder Kapitalerhöhung

Tradition halt

Unter trump ist der stock market explodiert

Wenn es ein Präsidentwechsel in der USA gibt, dann geht es am Markt nach oben bei allen Aktien. Der trump hat un soviel Geld gekostet, owey

Das ohne company news

Und insgesamt fast 130 Millionen aktien gehandelt

Plus 50%

Thx grinch 👍

https://stockhead.com.au/health/the-asx-pot-stocks-looking-to-get-high-on-canadas-3bn-market/

Passiert nur nix

https://***.com.au/threads/ann-preliminary-final-report.5596745/

Schauz gut aus

2020 PRELIMINARY FINANCIAL RESULTS Cann Global (ASX: CGB) (“company” or “Group”), a global medicinal cannabis, hemp seed and wellness corporation, is pleased to announce its results for the 12 months ended 30 June 2020 (FY20). Accompanying this release is the Appendix 4E and Preliminary Financial Report for FY20. CANN GLOBAL FY2020 RESULTS: HIGHLIGHTS Level 21, 133 Castlereagh Street, Sydney NSW 2000 - Australia Telephone: (02) 8379 1832 sfeldman@canngloballimited.com Cann Global Limited - ABN 18 124 873 507 www.canngloballimited.com ASX ANNOUNCEMENT 31 AUGUST 2020 Revenue for FY20 was $1,805k1 , a 275% increase on the prior year (FY19: $481k) due to the expansion into plant-based food products with the acquisition of T12 Holdings as well as strong organic sales growth. The food division was the primary driver of revenue generation, delivering $1,630k for FY20, an increase of 232% on the prior year (FY19: $481k) Cann Global Thailand Pty Ltd (55% owned) achieved a first-year profit of $143,250 The Group delivered a Gross Profit of $470k compared to a loss of $82k in the prior year Expenses (excluding finance costs) were reduced 20% during the year to $6,660k (FY19: $8,364k), despite a significant increase in research investment expenses during FY20 The Group reported a total loss of $8,050k, 13% better than the previous year (FY19: $9,234k) As at 30 June 2020, the Company had a healthy $7.4 million in cash reserves which has been further increased following the company’s July rights issue Product developments during the year included Chia oil soft-gel capsules, a new petfood range and significant progress towards bringing a suite of cannabinoid formulations developed by venture partner CannTab Therapeutics to Australia and Asia. Cann Global continues to seek appropriate regulatory approvals to facilitate distribution of new products globally and supports research initiatives in medicinal cannabis in what remains an emerging market and a significant opportunity.

News out

Das teil hier ist einfach schrott. Warten auf n hype dann nix wie raus